TAKARA BIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,008 JPY | -0.10% |
|
-2.51% | -19.49% |
| May. 10 | Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024 | CI |
| Mar. 18 | Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 59 times its estimated earnings per share for the ongoing year.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -19.49% | 776M | - | ||
| +51.85% | 57.87B | B- | ||
| +41.59% | 40.25B | A | ||
| -5.25% | 39.94B | B | ||
| -5.16% | 28.54B | C | ||
| +12.79% | 26.4B | B- | ||
| -20.18% | 19.33B | B | ||
| +30.88% | 12.4B | C+ | ||
| +0.61% | 12.23B | B+ | ||
| +25.06% | 12.2B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4974 Stock
- Ratings Takara Bio Inc.
